NEW YORK (GenomeWeb News) – Cancer Genetics plans to raise more than $29 million from its initial public offering, the company said in its amended Form S-1 yesterday.

In the document filed with the US Securities and Exchange Commission, the Rutherford, NJ-based cancer diagnostics firm said it anticipates net proceeds of $29.3 million from the offering. If the underwriters on the offering exercise their over-allotment options in full that figure would increase to $34.2 million.

Aegis Capital and Feltl and Co. are listed as the underwriters on the Form S-1/A.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.